All > Aphasia > Frontotemporal Dementia

AV-1451 for Apraxia of Speech

Mayo Clinic, Rochester, MN
Apraxia of Speech+4 More ConditionsAV-1451 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers understand how changes in the brain affect the progression of speech and language problems in people with neurodegenerative AOS.

Eligible Conditions
  • Apraxia of Speech
  • Primary Progressive Aphasia
  • Primary Progressive Nonfluent Aphasia
  • Aphasia Non Fluent

Treatment Effectiveness

Phase-Based Effectiveness

3 of 3
Phase 4
This is further along than 93% of similar trials

Similar Trials

1
Transcranial direct current stimulation
1
ASSIST
1
C-11 PiB

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: approxiamtely 1-2 years after baseline imaging

Year 2
Aphasia

Trial Safety

Phase-Based Safety

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Transcranial direct current stimulation
1
ASSIST
1
C-11 PiB

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo Group
All patients enrolled in this trial will receive the new treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1 Treatment Group

Tau positron emission tomography (PET)
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: AV-1451 · No Placebo Group · Phase 4

Tau positron emission tomography (PET)
Drug
Experimental Group · 1 Intervention: AV-1451 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approxiamtely 1-2 years after baseline imaging

Who is running the clinical trial?

National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
298 Previous Clinical Trials
176,780 Total Patients Enrolled
4 Trials studying Apraxia of Speech
176 Patients Enrolled for Apraxia of Speech
Mayo ClinicLead Sponsor
3,005 Previous Clinical Trials
3,512,630 Total Patients Enrolled
3 Trials studying Apraxia of Speech
715 Patients Enrolled for Apraxia of Speech
Jennifer Whitwell, PhDPrincipal Investigator - Mayo Clinic
Mayo Clinic
2 Previous Clinical Trials
359 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Is there still availability for participation in this research endeavor?

"According to clinicaltrials.gov, the current search for participants began on July 1st 2018 and was last modified in November of 2022 - indicating that they are still actively recruiting patients." - Anonymous Online Contributor

Unverified Answer

To what extent can AV-1451 be detrimental to human health?

"AV-1451's safety has been authenticated through Phase 4 trials, so its rating is a 3 on our scale." - Anonymous Online Contributor

Unverified Answer

How many individuals have volunteered for participation in this research?

"Affirmative. According to the details found on clinicaltrials.gov, this study is now enrolling patients who meet its eligibility criteria. This experiment was first listed on July 1st 2018 and last revised November 1st 2022; 50 participants are being recruited from a single location." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top